A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database
Open Access
- 23 February 2026
- journal article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Abstract
Background: Early diagnosis of primary or light chain (AL) amyloidosis is crucial for initiating appropriate therapeutic interventions. However, diagnosis is getting delayed (several months-to-years) in clinical practice. Objective: To investigate the real-world patterns of clinical procedures until initial diagnosis of AL amyloidosis in Japan. Design: Retrospective longitudinal, observational cohort study. Methods: This study included adults with AL amyloidosis using Medical Data Vision claims database (2003–2022). The primary endpoint was time from initial hospital visit until confirmed AL amyloidosis diagnosis. Symptoms, lab tests, and medical department visits until diagnosis, and mortality were analyzed. Results: Overall, 323 patients with AL amyloidosis were included (median age: 73.0 years). Median time to confirmed diagnosis was 81.5 days; reported longer in patients aged ⩾65 years versus <65 years, and Charlson Comorbidity Index ⩾4 than 1 year). Conclusion: These real-world data from Japanese AL amyloidosis patients are crucial for early and effective treatment, leading to better prognosis.Keywords
Funding Information
- Janssen Pharmaceuticals, K.K. Japan
This publication has 21 references indexed in Scilit:
- Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019European Journal of Haematology, 2021
- Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021Blood Cancer Journal, 2021
- A Changing Landscape of Mortality for Systemic Light Chain AmyloidosisJACC: Heart Failure, 2019
- Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in JapanInternal Medicine, 2018
- Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosisAmyloid, 2017
- Light Chain (AL) Amyloidosis: The Journey to DiagnosisThe Patient - Patient-Centered Outcomes Research, 2017
- Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosisHaematologica, 2015
- Guidelines on the diagnosis and investigation of AL amyloidosisBritish Journal of Haematology, 2014
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Misdiagnosis of Hereditary Amyloidosis as AL (Primary) AmyloidosisNew England Journal of Medicine, 2002